OncoMatch/Clinical Trials/NCT02185443
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
Is NCT02185443 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for liver metastases.
This is a Phase II study to determine the efficacy of SBRT to treat liver metastases in patients with Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors that are not amenable to surgery. Patients should have no evidence of extra-hepatic disease or have disease that is planned to be treated with curative intent. Therefore, SBRT is being considered as a potentially curative procedure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Neuroendocrine Tumor
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
absolute neutrophils count > 1,800 cells / mm3; platelets > 100,000 cells / mm3; hemoglobin > 8.0 g / dl (transfusion or other intervention accepted)
Liver function
No active hepatitis or clinically significant liver failure
Adequate bone marrow function defined as: absolute neutrophils count > 1,800 cells / mm3; platelets > 100,000 cells / mm3; hemoglobin > 8.0 g / dl (transfusion or other intervention accepted); Active hepatitis or clinically significant liver failure [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify